First-line Treatment of Dalpiciclib Combined With Pyrotinib for HER2+ Advanced Breast Cancer(DAP-Her-02)
Status:
Not yet recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
Based on different HR status, we explored the efficacy and safety of Pyrotinib and
Dalpiciclib Isethionate Tablets based combination regimen in the first-line treatment of HER2
+ MBC.